Clinical Trials Browser

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT00494442 2018-08-01

ICEBERG 2

Phase 2 Completed

58 enrolled 13 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00419510 2016-08-17

Genetic Counseling in African American Women

Phase NA Completed

204 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT01346761 2016-04-14

REACH

Phase NA Completed

1,012 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms, Genetic Predisposition to Disease

NCT01772979 2013-01-21

MITO15

Phase 2 Unknown

100 enrolled

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Phase NA Completed

150 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

LUSTIC

Methods in Education for Breast Cancer Genetics

ICEBERG 3

REVIVAL

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

ICEBERG 2

Genetic Counseling in African American Women

REACH

MITO15

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing